In one of the most-watched patent cases in recent times, the Indian Patent Office on Thursday rejected American giant Johnson & Johnson’s (J&J) attempt to extend its monopoly on life-saving TB drug bedaquiline beyond July this year. The development made public coincidentally on the eve of the World TB Day — will improve access to the core drug, Bedaquiline, which is part of the WHO recommended all-oral TB regimen.
from Times of India https://ift.tt/KzM50u9
via IFTTT
Post a Comment